37 results about "Colorectal adenocarcinoma" patented technology

A method and apparatus for determining the progressive potential of a disease is disclosed. The forward to backward propagating second harmonic generation signal derived from a second harmonic generation instrument is used to assess the collagen microstructure of imaged body tissue by way of numerical values that are in turn used to determine the progressive or metastatic potential of the disease. The disease may, for example, be a cancer such as breast cancer, lung fibrosis, colorectal adenocarcinoma, or the like. The apparatus may include in vivo instruments or laboratory diagnostic instruments with methods disclosed herein.

The present invention relates to in vitromethods and compositions for diagnosing and / or treating a colorectal adenocarcinoma associated with a chromosomal aberration on chromosome 20q and / or the predisposition for developing such an adenocarcinoma by determining the expression levels of a set of particular marker genes, wherein an elevated expression level of the marker genes in a test sample as compared to a control level is indicative of a colorectal adenocarcinoma.

The invention provides a polypeptide marker Pep5 enzyme-linked immunosorbent assay (ELISA) kit which contains a monoclonal antibody which is labeled by enzyme and secreted by monoclonal antibody hybridoma cell line with a China general microbiological culture collection center (CGMCC) No. 5269. The kit prepared by the monoclonal antibody secreted by the hybridoma cell line can be used for detecting colorectal adenocarcinoma, and is simple, convenient and rapid to operate, beneficial to high flux clinical detection and low in detection cost.

The invention provides a nifurazide derivative and its preparation method and application, belonging to the field of chemical medicine. The structure of the nifurazide derivatives is shown in formula I. The nifurazide derivatives can effectively inhibit the proliferation of fibroblasts and the proliferation of human hepatic stellate cells, and most of the compounds have better inhibitory effects than nifurazide. The derivative can also reduce the proliferation of collagen fibers in the lung tissue of mice with pulmonary fibrosis, improve the interstitial fibrosis of mice, maintain the normal lung structure of mice, and even reverse the changes in lung structure of mice with pulmonary fibrosis. Humanized mice have good therapeutic effects and can be used to prepare candidate drugs for preventing and / or treating fibrosis. At the same time, the derivative has an excellent inhibitory effect on the proliferation of various tumor cells including breast cancer, colorectal adenocarcinoma, colon cancer and liver cancer, and can be used to prepare drug candidates for the prevention and / or treatment of various tumors. bright future.

The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset and / or progression of a large intestine or breast neoplasm, such as an adenoma or adenocarcinoma. The DNA methylation status of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and / or monitoring of colorectal or breast neoplasms, such as colorectal or breast adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening for the onset, predisposition to the onset and / or progression of a neoplasm by screening for modulation in DNA methylation of one or more nucleic acid molecules. The nucleic acid molecules used for diagnostics in the present invention are sequences from LOC 100526820, subsequently named CAHM (colorectal adenocarcinoma hypermethylated).

The present invention discloses methods and tools for reliably detecting the presence of adenocarcinoma cells in a patient, at the genetic level. The present invention fine-maps the regions of chromosomal aberrations linked to progression of adenomas into adenocarcinoma cells and provides methods and tools for detection based thereon.

The invention discloses diosgenin hydroxamic acid derivatives and their preparation method and application. Diosgenin is used as a lead compound to prepare a series of hydroxamic acid derivatives through corresponding chemical reactions, and the anti-tumor effect of the derivatives Applications. Pharmacological experiments show that: all synthesized diosgenin hydroxamic acid derivatives are treated with CCK8 method against SW620 (human colon adenocarcinoma cells), H358 (human non-small cell lung cancer cells), HCT‑116 (human colorectal adenocarcinoma cells) and Aspc‑1 (human metastatic pancreatic cancer cells) were tested for antiproliferative activity in vitro. Experimental results show that most of the derivatives have better anti-tumor activity than diosgenin on cells.

The invention discloses a novel ceramide analogue A and a preparation method and application thereof, and belongs to the technical field of medicaments. The novel ceramide analogue structure introduces two amino groups to improve the carbonyl electronegativity between the two amino groups, and halogen is introduced at the tail end, so that the novel ceramide analogue is easier to combine with enzyme; the novel ceramide analogue has cis-double bonds, the solubility of molecules is improved, and the space trend of long chain connected with the double bonds is changed; the novel ceramide analoguecan not only inhibit the proliferation of tumor cells, but also have obvious influence on the differentiation and cycle of leukemia tumor cells, thereby being beneficial to multi-way tumor prevention; the novel ceramide analogue shows better performance in inhibiting human colorectal adenocarcinoma cell LS174T than positive control C6, shows a leader molecule with antitumor application potentialand has certain proliferation promoting effect on cancer cells.

The invention belongs to the technical field of medicinal chemistry, and specifically relates to a multi-substituted naphthoquinone derivative and its preparation method and application. The structure of the derivative is shown in the general formula (I), wherein, R 1 selected from ethoxy, diphenylmethoxy, linalyl, D-menthol; R 2 selected from thiophene, phenyl, p-bromophenyl, p-methoxyphenyl, 2,4,6-trimethylphenyl; R 3 selected from hydrogen, nitro; R 4 Selected from hydrogen, fluorine, and bromine; the derivative has a novel structure and has a good antitumor effect, especially has a good inhibitory effect on colorectal adenocarcinoma cells, osteosarcoma cells and breast cancer cells. It has great application value and is expected to be prepared as an antitumor drug; at the same time, the preparation method of the polysubstituted naphthoquinone derivative has fewer reaction steps, simple and safe operation, low cost, less waste generation, high atom economy, and high selectivity. Sex, the advantage of high yield.

The invention relates to a quinoline multi-target kinase inhibitor with antitumor activity and a preparation method thereof. A general structural formula of the compound is shown in a formula (I) described in the specification. In vitro cell experiments verify that the compound provided by the invention has strong in vitro inhibitory activity on five common tumor cell lines, namely human thyroid carcinoma SW579, human hepatic carcinoma HepG2, human lung adenocarcinoma A549, human colorectal adenocarcinoma HCT116 and human gastric carcinoma MKN45, antitumor activities of most of target compounds are better than or equivalent to that of a positive control drug Cabozantinib, and the in vitro cell experiments verify that the compound provided by the invention has strong inhibitory activity on two kinases KDR and MET, so that the compound provided by the invention has a broad application prospect in preparation of a new antitumor drug.

The invention provides a human colorectal adenocarcinoma tumor cell line as well as a preparation method and an application thereof. The cell line P6C of human colorectal adenocarcinoma tumor stem cell line has the preservation number of CGMCC No.5558. The preparation method comprises the following steps of: 1) separating original colon cancer stem cells; 2) culturing the primary colon cancer stem cells in vitro; 3) culturing and identifying the colon cancer stem cells; and 4) separating and culturing the obtained colon cancer stem cells according to the same method in the steps 1), 2) and 3) to screen and express the tumor stem cell of CD44 membrane protein. The cell line can be applied in the preparation of the medicine for inducing tumour formation, a medicine for tumor metastasis and medicines for screening antituvmorigenesis, anti-tumor growth and anti-tumor metastasis.